---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-026790"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2026-08-10T20:35:21+00:00"
generated_at: "2026-08-10T20:37:20.348605+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# DiaMedica Q2 loss $10.1M; PE trial shows 29.1 mmHg SBP drop

## Summary
- Net loss $10.1M in Q2 2026 vs $7.7M Q2 2025; six-month loss $20.2M vs $15.4M.
- Cash $43.5M at June 30, 2026 vs $59.9M at Dec 31, 2025; runway through 2027.
- Phase 2 PE Part 1a: DM199 reduced SBP 29.1 mmHg (p<0.001) from 169.3 mmHg baseline; DBP 17.0 mmHg.
- FGR Phase 2 first cohort of 6 patients (5 µg/kg) fully enrolled; topline results due September.
- ReMEDy2 AIS trial enrollment >85% of 200 patients; interim analysis expected Q1 2027.

## SEC filing metadata
- accession: 0001437749-26-026790
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2026-08-10T20:35:21+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774926026790/0001437749-26-026790-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774926026790/dmtp20260809_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-026790
- JSON: https://secwatch.observer/filing/0001437749-26-026790.json
- Plain text: https://secwatch.observer/filing/0001437749-26-026790.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.